Physician profile
Patrick E Davol
NPI 1003025875
$5,496.52
in general payments reported to CMS, 2019-2025
32 companies · $299 in 2025
The $299 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,238 · 2020: $312 · 2021: $201 · 2022: $754 · 2023: $631 · 2024: $2,062 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,507 · Travel and Lodging: $1,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.51 |
| Travel and Lodging | $1,484.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $1,703.34 | 2024 | Aquabeam System |
| Astellas Pharma US INC | $542.73 | 2019-2024 | Myrbetriq, Xtandi |
| Boston Scientific Corporation | $541.52 | 2019-2025 | Spaceoar Vue System - 10ml, Rezum Generator, Lithovue Elite |
| Abbvie INC. | $437.78 | 2020-2024 | Botox |
| Coloplast Corp | $326.77 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $243.98 | 2020-2022 | |
| Allergan, INC. | $224.37 | 2019-2020 | |
| Intuitive Surgical, INC. | $203.94 | 2020-2023 | Da Vinci Surgical System |
| Ferring Pharmaceuticals INC. | $134.52 | 2019 | |
| 180 Medical, INC. | $128.72 | 2023-2025 | Cure Catheter |
| Pfizer INC. | $122.82 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.10 | 2019-2023 | |
| Myriad Genetic Laboratories, INC. | $114.17 | 2022-2025 | Prolaris, Myrisk |
| Janssen Biotech, INC. | $87.73 | 2019-2025 | Erleada |
| Sumitomo Pharma America, INC. | $64.57 | 2023 | Orgovyx |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $54.20 | 2022 | |
| Histosonics, INC. | $51.28 | 2025 | |
| Endo Pharmaceuticals INC. | $48.00 | 2019-2023 | Aveed, Xiaflex |
| Travere Therapeutics, INC. | $41.33 | 2019-2021 | |
| Olympus America INC. | $40.00 | 2019 | |
| Ambu INC. | $31.53 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $30.46 | 2025 | |
| Cook Medical LLC | $27.50 | 2020 | |
| Urovant Sciences INC | $26.14 | 2022 | |
| Tolmar, INC. | $25.46 | 2025 | Jatenzo, Eligard |
| Alnylam Pharmaceuticals INC. | $25.29 | 2022 | |
| Genzyme Corporation | $23.87 | 2022 | |
| Endo USA, INC. | $18.84 | 2025 | Aveed, Xiaflex |
| Amgen INC. | $16.86 | 2022 | |
| Baxter Healthcare | $15.41 | 2023 | Tisseel |
| Tolmar Pharmaceuticals, INC. | $14.33 | 2019 | |
| Dendreon Pharmaceuticals LLC | $13.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Davol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.